To evaluate the efficacy and safety of a new, once-daily prolonged-release formulation of the uroselective alpha 1-adrenoreceptor antagonist, Alfuzosin in Korean patients with benign prostatic hyperplasia (BPH). The study comprised 21 patients with symptomatic BPH who received 10mg Alfuzosin once daily for 3 months. The efficacy variables assessed were an international prostatic symptom score (IPSS), quality of life (QOL) index, changes in maximum and average urinary flow rate (Qmax and Qave), postvoid residual urine volume, pulse rate and blood pressure. Questionnaires and parameters were measured at baseline, 1 month and 3 month during the study. Seventeen patients were included in the analysis and 4 patients dropped out, unable to follow up. IPSS improved from 18.5 to 15.5, especially in obstructive symptoms greater than in irritative symptoms, between the baseline and the endpoint of the study. QOL index also improved significantly, from 4.4 to 3.1 (p<0.05). A significant increase in Qmax was obtained from 11.1 to 15.0 (p<0.05). Blood pressure and pulse rate remained unchanged during 3 months. Alfuzosin was well tolerated, with only 1 out of 21 patients reported dizziness. This study showed beneficial short-term results for the efficacy and safety of prolonged-release formulation of Alfuzosin in the management of symptomatic BPH.